← Leaderboards
Robert Charles Moen
Inomagen Therapeutics, Inc
$3,849,106
Attributed
$3,849,106
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2021–23$2M$1.5M$1M$500K$0
'21
'22
'23
Funding mix
By agency
NIH$3,849,106 · 1
By mechanism
R44$3,849,106 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Ablation”
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,064,669
- Kenneth B. Bader · University Of Chicago$6,109,156
- John R Lukens · University Of Virginia$5,842,869
- Juliette Elizabeth McGregor · University Of Rochester$5,567,728
- Jie Shen · Washington University$5,388,462
- Ashley E Webb · Brown University$5,147,077
Research focus
AblationAge RelatedAging PopulationAffectAnti-Arrhythmia AgentsAtrial FibrillationAttenuatedAutonomic NerveAutonomic Nervous SystemAmericanBiodistributionBiologicalBiological ProductsBiological Response Modifier TherapyCanis FamiliarisCardiacCathetersClinical ResearchCommercial ApplicationCoronary Sinus StructureCostDevicesDoseElectrophysiology (Science)
Grant awards (3)
A New and Disruptive Gene Based Therapy for Atrial Fibrillation$1,749,913
R44 · FY2023 · HL · contact PI
A New and Disruptive Gene Based Therapy for Atrial Fibrillation$1,636,504
R44 · FY2022 · HL · contact PI
A New and Disruptive Gene Based Therapy for Atrial Fibrillation$462,689
R44 · FY2021 · HL · contact PI